Results 81 to 90 of about 14,668 (165)

Bridging Randomized Trial Efficacy and Real‐World Effectiveness in Multiple Myeloma: Integrating Clinical Trials and Real‐World Evidence for Individualized Care

open access: yesEuropean Journal of Haematology, Volume 117, Issue 5, Page 1181-1197, November 2026.
ABSTRACT Multiple myeloma (MM) is predominantly a disease of older adults, yet the randomized clinical trials (RCTs) that define standards of care are conducted largely in younger, fitter, and less comorbid populations. This creates a systematic mismatch between the populations generating evidence and those receiving treatment in routine practice ...
Enrica Antonia Martino   +13 more
wiley   +1 more source

Comment on: International multicentre evaluation of a new anti‐idiotypic anti‐daratumumab for resolving pre‐transfusion interferences

open access: yes
Vox Sanguinis, EarlyView.
Yonka Lazarova   +4 more
wiley   +1 more source

Breakthrough Hemolysis in Paroxysmal Nocturnal Hemoglobinuria: Mechanistic Insights and Management Strategies

open access: yesTransfusion, Volume 66, Issue 11, Page 2421-2431, November 2026.
Abstract Background Paroxysmal nocturnal hemoglobinuria (PNH) is a clonal hematopoietic stem cell disorder caused by somatic mutations in the PIGA gene, resulting in loss of glycosylphosphatidylinositol (GPI)‐anchored proteins, including the complement regulatory proteins, CD55 and CD59.
Ganesh Raman   +4 more
wiley   +1 more source

Pretransfusion testing interference profile of IMC‐002: A novel anti‐CD47 monoclonal antibody engineered for minimized red cell binding

open access: yesTransfusion, Volume 66, Issue 11, Page 2323-2334, November 2026.
Abstract Background CD47‐targeted agents can interfere with pretransfusion testing due to CD47 expression on red blood cells (RBCs). IMC‐002 is a novel anti‐CD47 human IgG4 monoclonal antibody engineered to minimize RBC binding; however, its interference profile during pretransfusion testing remains poorly characterized.
Tae‐Shin Kim   +5 more
wiley   +1 more source

Risque infectieux associé au daratumumab en traitement du myélome

open access: yes, 2020
Le daratumumab, anticorps monoclonal ciblant le CD38, fait partie des nouvelles thérapies ayant transformé l'approche thérapeutique du myélome ces dernières années, mais son impact sur l'immunité et le risque infectieux reste incertain.
Lacroix, Mathilde
core   +1 more source

Implementation of soluble CD38 in blood crossmatching for patients on anti‐CD38 therapy: A single‐center experience

open access: yesTransfusion, Volume 66, Issue 11, Page 2097-2100, November 2026.
Abstract Background Human monoclonal (MoAb) anti‐CD38 antibodies, such as daratumumab, are used to treat diseases such as multiple myeloma. Because red blood cells (RBCs) express CD38, these MoAbs interfere with antibody screening and crossmatching in blood banks.
Ayda Javanbakht   +3 more
wiley   +1 more source

Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma

open access: yes, 2017
Key PointsNo new safety signals were observed with daratumumab plus pomalidomide and dexamethasone, except for increased neutropenia. Daratumumab plus pomalidomide and dexamethasone induced rapid, deep, and durable responses in heavily treated patients ...
Nushmia Z. Khokhar   +15 more
core   +1 more source

Daratumumab for Immunoglobulin Light Chain Amyloidosis

open access: yes, 2021
Immunoglobulin light chain (AL) amyloidosis is characterized by small, indolent plasma cell clones that uniformly demonstrate high expression of CD38 surface molecule and produce toxic, free light chains.
Theodorakakou, Foteini   +2 more
core   +1 more source

A prospective, phase IV study of ixazomib, pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma

open access: yes
British Journal of Haematology, Volume 209, Issue 5, Page 2316-2320, November 2026.
Runfeng Zhang   +15 more
wiley   +1 more source

Response to daratumumab-retreatment in patients with multiple myeloma

open access: yes
Daratumumab is an effective therapy in multiple myeloma (MM). We assessed whether daratumumab retreatment may re-induce significant responses and which patients do benefit the most.
Ihorst, Gabriele   +4 more
core   +1 more source

Home - About - Disclaimer - Privacy